POST TRAUMATIC STRESS DISORDER: NEURO-BIOTECH ADDRESSES A FOCUSED APPROACH

BASEL, Switzerland, Feb. 9 /CNW Telbec/ - Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB: MRES), having recently signed a Business Development Agreement with Russian based Credo-TM, who in turn had just finished negotiations for 1,000,000 Post Traumatic Stress Disorder (PTSD) test with their nation's military forces to help with early detection of PTSD which is an ongoing concern for worldwide military forces.

Stress, as defined by Hans Selye in 1945, could be expressed in regards to active military people first as a physical stress - we know that active military people are trained to be able to physically react to specific situations. It could also be expressed as a mental stress - active military people are also well trained in regards to alertness, vigilance, attention or automatisms related to their equipments. Finally, it can be expressed too in the form of emotional stress - it is the link to work with PTSD.

The human emotional memory is the basis of PTSD. In fact, the brain is used to receive all kind of information through our five senses, to retain and integrate it, to remember and initiate the emotions through "FLASHBACKS".  In PTSD, such emotional information is so strong that it is impossible to forget it. However, it is possible to manage with it through recognition and acceptation process.

Some statistical data have clearly demonstrated that PTSD is present in the population. Thus, in USA, 5,600,000 people are affected, 1,600,000 in Germany, 1,200,000 in France, 1,600,000 in Egypt while in Switzerland, less than 200,000 people are affected by PTSD. These data are in good correlation with the WHO saying in its 2000's Report "Stress - a century's disease".

For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com

CONTACT
Neuro-Biotech Corp.
Dr. Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com

FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

SOURCE Neuro-Biotech Corp.

For further information:

CONTACT
Neuro-Biotech Corp.
Dr. Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com

Profil de l'entreprise

Neuro-Biotech Corp.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.